

# Lyophilized Injectables Market to Hit \$4.6 Billion by 2031, Driven by Biologics and Drug Delivery Innovation

*Rising biologics demand, chronic disease cases, and R&D investment fuel growth of lyophilized injectables to \$4.6B by 2031.*

LOS ANGELES, CA, UNITED STATES, June 26, 2025 /EINPresswire.com/ --

## [Lyophilized Injectables Market Size](#)

Lyophilized Injectables Market Size reached US\$ 3.1 billion in 2023 and is expected to reach US\$ 4.6 billion by 2031, growing at a CAGR of 5.2% during the forecast period 2024-2031.

Lyophilized injectables are medications that undergo a freeze-drying process to remove moisture, resulting in a stable, solid form. This technique enhances the shelf life and stability of drugs, particularly sensitive biologics and vaccines, which are typically reconstituted with a liquid before use.

The global demand for lyophilized injectables is being fueled by several key factors, including the increasing development of complex biologics and molecules, advancements in drug delivery systems, innovations in lyophilization technology, a rising prevalence of chronic diseases, and the expanding market for biopharmaceutical products.

“

Lyophilized Injectables Market Size reached US\$ 3.1 billion in 2023 and is expected to reach US\$ 4.6 billion by 2031”

*DataM Intelligence*

**DATA**  
INTELLIGENCE



Info@datamintelligence.com

Lyophilized Injectables Market size reached **US\$ 3.1 billion in 2023** and is expected to reach **US\$ 4.6 billion by 2031**, growing at a **CAGR of 5.2%** during the forecast period 2024-2031.

Lyophilized Injectables Market 2025

Download Sample Report:

<https://www.datamintelligence.com/download-sample/lyophilized-injectables-market>

Lyophilized Injectables Market Growth  
Growth in Biologics and Complex Molecules

The global lyophilized injectables market is experiencing significant growth, largely driven by the

increasing development of biologics and complex therapeutic molecules. Biologics medications derived from living organisms are playing an expanding role in treating a variety of conditions, including autoimmune disorders, infectious diseases, and various forms of cancer.

These advanced therapies offer precise, targeted treatment options that improve patient outcomes and address unmet medical needs. Lyophilized injectable formulations are crucial for the effective delivery of biologics, as they help preserve the drug's stability and bioactivity during storage and transportation.

Pharmaceutical companies often collaborate with Contract Manufacturing Organizations (CMOs) to leverage their specialized expertise, advanced infrastructure, and lyophilization capabilities for the development and production of these complex injectable drugs.

A notable example is Pfizer's initiative in May 2022 to launch a global drug development center in India. This facility focuses on producing finished dosage forms (FDFs) of high-value products, including lyophilized injectables, complex formulations, controlled-release drugs, device-integrated therapies, powder-fill solutions, and ready-to-use formulations.

#### Lyophilized Injectables Market Segments

By Drug Type (Anti-infective, Anti-neoplastic, Anticoagulant, Hormones, Others)

By Type of Delivery (Multi-step Devices, Prefilled Diluent Syringes, Proprietary Reconstitution Devices, Single-step Devices)

By Form (Powder, Liquid)

By Route of Administration (Intravenous/Infusion, Intramuscular, Others)

By Application (Autoimmune Diseases, Infectious Diseases, Metabolic Conditions, Oncology, Others)

By Type of Packaging (Point-of-Care Reconstitution, Specialty Packaging, Single-use Vials)

By End-User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Others)

#### Lyophilized Injectables Market Key Players

Key players are Merck & Co., Inc., Protech Telelinks, Cirondrugs, Aristopharma Ltd, Pfizer Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Sanofi, Amgen Inc and Novo Nordisk A/S.

#### Recent Industry Developments

In May 2024, Global contract development and manufacturing organization (CDMO), Sterling Pharma Solutions, announced that it has invested \$3 million into expanding its integrated antibody-drug conjugate (ADC) development and manufacturing capabilities in its Germantown, Wis. facility in the United States.

In July 2023, WuXi STA, a contract research development and manufacturing organization (CRDMO) that functions as a subsidiary of WuXi AppTech, announced the launch of its first high potency (HP) fully automated sterile injectable manufacturing line at its drug product site in Wuxi City, China.

Market leadership & R&D: North America dominates ~42% of the global lyophilized injectables market, driven by robust pharma R&D investment, advanced healthcare infrastructure, and strong FDA oversight. The U.S. accounts for over 40% of the global lyophilized microspheres

service sector.

Related Trending Reports:

[Facial Injectables Market](#)

[Injectable Cytotoxic Drugs Market](#)

Sai Kiran

DataM Intelligence 4Market Research

+1 877 441 4866

Sai.k@datamintelligence.com

Visit us on social media:

[LinkedIn](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/825831744>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.